BioLineRx Corporation - BLRX Company Short-Term Debt

BioLineRx Corporation (BLRX) - corporate logo

Premium pricing for stem cell therapy in the US is constrained by insurance limits, yet the short-term borrowings of BioLineRx Ltd. (BLRX) clearly demonstrate current liquidity, where the 0.01 mark records this indicator. Global research risks are amplified by geopolitical barriers and logistical gaps. The stability of BioLineRx Ltd. (BLRX) is ensured by a diversified portfolio of oncology and genetic programs, combining commercial sales with early-stage development.

BLRX (BioLineRx) Company Short-Term Debts history from 07/04/2022 to 10/28/2026

BioLineRx Corporation - analytical breakdowns and key metrics (BLRX)

- price and consensus price forecast:
Stock Price BioLineRx|BLRX - Average Forecast Price
- market capitalization data:
Market Value BioLineRx Ltd.|BLRX - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share BioLineRx|BLRX - Book Capitalization|Market Value to Book Value Ratio biolinerx.com|BLRX - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio BioLineRx Ltd.|BLRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity BioLineRx Ltd.|BLRX - Company Cumulative Debt|Debt to Book Capitalization Ratio BioLineRx Ltd.|BLRX - Company Long-Term Indebtedness|Company Short-Term Debts BioLineRx
Fundamental company valuation:BioLineRx Ltd.
Signature product of BioLineRx Ltd.

Short-term debt measures the total liabilities maturing within one year, reflecting liquidity dependence on the ability to generate operating cash flow. By analyzing historical short-term debt data, an investor can assess whether the expansion of BioLineRx Ltd. (BLRX) in the US market and the premium pricing of its therapy are capable of offsetting the credit burden amid strict insurance limits.

Competitors of BioLineRx Ltd. (BLRX)

INCY (Incyte) - Company Short-Term Debts|HCM: Short-Term Debt|Company Short-Term Debt Nuvation Pharma NUVB|Day One Biopharmaceuticals Inc (DAWN) - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts INBX|Company Short-Term Debt I-Mab (IMAB)|Company Short-Term Debt Fennec Pharma FENC|Company Current Liabilities Heron Therapeutics, Inc.|Nuvectis Pharma, Inc - Company Short-Term Loans and Borrowings|CHRS (Coherus BioSciences, Inc.) - Company Short-Term Debt|CRBP: Short-Term Debt|Company Short-Term Debt cardiffoncology.com|BeyondSpring, Inc. (BYSI) - Company Short-Term Indebtedness|Company Short-Term Debts BCAB|Company Current Liabilities LIXT|Citius Pharmaceuticals - Company Short-Term Debt|Short-Term Debt CLRB (cellectar.com)|Company Short-Term Debt Can-Fite BioPharma Ltd. CANF|Aprea Therapeutics Inc. - Company Short-Term Debt|KZIA (Kazia) - Company Short-Term Debt|SLXN - Short-Term Debt|Company Short-Term Debts NCNA (nucana.com)|Short-Term Indebtedness chimerix.com|Company Current Liabilities CYCC (Cyclacel)|Short-Term Debt G1 Pharma (GTHX)|Kronos Bio Corp (KRON) - Company Current Liabilities|Company Short-Term Loans and Borrowings Kintara Pharma KTRA|Company Current Liabilities Oncternal Therapeutics (ONCT)|Amount of Current Liabilities portagebiotech.com PRTG